×
About 4,665 results

ALLMedicine™ Narcolepsy Center

Research & Reviews  1,341 results

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04794491

Jun 24th, 2022 - The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.

Pfizer/BioNTech SARS-CoV-2 vaccine as a potential trigger for the development of narcol...
https://doi.org/10.5664/jcsm.10134
Journal of Clinical Sleep Medicine : JCSM : Official Publ... Mahamid A, Bornstein RJ et. al.

Jun 24th, 2022 - Narcolepsy is a rare condition in Israel. Currently, the incidence of narcolepsy following SARS-CoV-2 vaccination in Israel is unknown. We are reporting a case report of a 51-year-old female of Ashkenazi Jewish descent who was evaluated for compla...

Characterising the background incidence rates of adverse events of special interest for...
https://doi.org/10.1136/bmj.n1435
BMJ (Clinical Research Ed.); Li X, Ostropolets A et. al.

Jun 22nd, 2022 - To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. Multinational network cohort study. Electronic health records and health claims data from eight countries: ...

Clarithromycin Mechanisms in Hypersomnia Syndromes
https://clinicaltrials.gov/ct2/show/NCT04026958

Jun 21st, 2022 - Excessive daytime sleepiness and long sleep durations are common features of many neurologic disorders, including myotonic dystrophy, Parkinson's disease, and the central nervous system hypersomnia syndromes. These latter syndromes are a group of ...

A comparison of mood, quality of life and executive function among narcolepsy type 1 pa...
https://doi.org/10.1016/j.sleep.2022.05.016
Sleep Medicine; Qu S, Wang P et. al.

Jun 20th, 2022 - To investigate the prevalence of core attention-deficit/hyperactivity disorder (ADHD) symptoms in Chinese narcolepsy type 1 (NT1) patients and to explore mood, quality of life, and executive function in narcolepsy patients with or without ADHD and...

see more →

Guidelines  1 results

Practice parameters for the treatment of narcolepsy and other hypersomnias of central o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276123
Sleep Morgenthaler TI, Kapur VK et. al.

Feb 6th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...

see more →

Drugs  215 results see all →

Clinicaltrials.gov  125 results

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04794491

Jun 24th, 2022 - The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.

Clarithromycin Mechanisms in Hypersomnia Syndromes
https://clinicaltrials.gov/ct2/show/NCT04026958

Jun 21st, 2022 - Excessive daytime sleepiness and long sleep durations are common features of many neurologic disorders, including myotonic dystrophy, Parkinson's disease, and the central nervous system hypersomnia syndromes. These latter syndromes are a group of ...

An Open Label Study of FT218 in Subjects With Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04451668

Jun 14th, 2022 - This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (reg...

Group Psychotherapy in Narcolepsy Type 1
https://clinicaltrials.gov/ct2/show/NCT05314556

Jun 3rd, 2022 - The aim of this pilot study is to test the benefit of behavior therapy-oriented, method-integrated psychotherapy in an outpatient group setting in patients with narcolepsy type 1. Therefore we collect and evaluate initial data on its effectiveness...

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
https://clinicaltrials.gov/ct2/show/NCT04923594

Jun 3rd, 2022 - This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-we...

see more →

News  170 results

Cupping in dermatology
https://www.mdedge.com/dermatology/article/253900/aesthetic-dermatology/cupping-dermatology
Chloe Goldman, MD

Apr 19th, 2022 - My inspiration to write about cupping this month stems from the perception that everyone seems to be talking about it, from a facialist who suggested it for me to a coworker who swears by cupping to treat her allergies. Cupping is by no means a no.

Stimulant Reduces Apathy in Alzheimer's Disease
https://www.medpagetoday.com/neurology/alzheimersdisease/94722

Sep 27th, 2021 - Treatment with methylphenidate (Ritalin), a stimulant approved for attention deficit-hyperactivity disorders (ADHD) and narcolepsy, led to a small to medium reduction in apathy in people with Alzheimer's disease, the phase III ADMET 2 trial showed...

COVID-19 mRNA Vaccines: No Serious Health Risks in Large Study
https://www.medscape.com/viewarticle/958205

Sep 3rd, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Serious health risks were no more common in the first 3 weeks after Pfizer/BioNTech or Moderna COVID-19 vaccination compared with 22-42 days later...

The future of Advanced Practice Providers (APPs) in sleep clinics and telemedicine post-pandemic
https://www.mdedge.com/clinicianreviews/article/244976/sleep-medicine/future-advanced-practice-providers-apps-sleep-clinics
Loretta Colvin, NP

Aug 30th, 2021 - Loretta J. Colvin, APRN, ACNP-BC, is a Nurse Practitioner at Sleep Services, SSM Health Medical Group, specializing in the treatment of sleep disorders.

Neurodegenerative nature of schizophrenia makes case for LAIs
https://www.mdedge.com/psychiatry/article/244762/schizophrenia-other-psychotic-disorders/neurodegenerative-nature
Jim Kling

Aug 27th, 2021 - Schizophrenia is a complex disease caused by dysfunction in specific brain regions or circuits. In fact, schizophrenia is not a single disease but several hundred different diseases, according to Henry A.

see more →

Patient Education  14 results see all →